11/03/2025
https://www.facebook.com/share/p/12FARwZxAAb/
Background: Monoclonal antibodies (mAbs) for anti-calcitonin gene-related peptide (CGRP) have emerged as an effective and well-tolerated option for alleviating migraine burden and improving patients’ quality of life. There is limited understanding of the specific clinical and biological predictors...